Real-World Validation of the Purity Independent Subtyping of Tumors Classifier for Informing Therapy Selection in Pancreatic Ductal Adenocarcinoma
Patients with PDAC of the PurIST classical subtype showed a significant OS benefit when treated with FFX as 1L versus GnP.
Authors
- Chithra Sangli
- Gregory M. Mayhew (ORCID: https://orcid.org/0009-0005-3082-2157)
- John Guittar (ORCID: https://orcid.org/0000-0002-8897-8841)
- James M. Davison (ORCID: https://orcid.org/0000-0003-2453-7227)
- Al B. Benson (ORCID: https://orcid.org/0000-0001-5485-7227)
- James L. Chen (ORCID: https://orcid.org/0000-0002-4095-5202)
- Farahnaz Islam (ORCID: https://orcid.org/0000-0002-8331-9871)
- Kirk D. Beebe (ORCID: https://orcid.org/0000-0001-5799-1608)
- Halla Nimeiri (ORCID: https://orcid.org/0000-0002-8760-6456)
- Kai M. Brown (ORCID: https://orcid.org/0000-0002-9649-7343)
- Michael V. Milburn
- Stéphane Wenric (ORCID: https://orcid.org/0000-0001-5625-2133)
- Charles M. Perou (ORCID: https://orcid.org/0000-0001-9827-2247)
- Alia Zander (ORCID: https://orcid.org/0000-0001-7211-9391)
- Justin Guinney (ORCID: https://orcid.org/0000-0003-1477-1888)
- Timothy Taxter (ORCID: https://orcid.org/0000-0001-6489-1007)
- Kyle A. Beauchamp (ORCID: https://orcid.org/0000-0001-6095-8788)
- Miral Patel
- Seung Won Hyun
Institutions
- Northwestern University (US)
- University of North Carolina at Chapel Hill (US)
- Tempus Labs (United States) (US)
Publication Details
- Journal
- JCO Precision Oncology
- Published
- 2025-09-01
- DOI
- https://doi.org/10.1200/po-25-00197
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00